Aspire Biopharma Holdings, Inc. 8-K

What Happened

• Aspire Biopharma Holdings, Inc. announced that at its Special Meeting of Stockholders on April 10, 2026, shareholders approved several corporate actions, including authorization for a reverse stock split, approvals related to issuance of shares tied to its Series A Convertible Preferred Stock and an ELOC financing agreement, and an increase in authorized common stock. The company filed the results on Form 8‑K on April 16, 2026.
• Key corporate mechanics approved include a board‑controlled reverse split at a ratio the board may choose between 1‑for‑5 and 1‑for‑500 (to be effected, if at all, within one year), Nasdaq‑related approvals to permit issuance of conversion shares from the Series A Preferred (including issuance above 19.99% of outstanding common stock and setting a conversion floor price equal to 20% of the Minimum Price), authorization to issue 19.99% or more of common stock under the ELOC Agreement with Arena Business Solutions Global SPC II, Ltd., and an increase in authorized common shares from 490,000,000 to 700,000,000.

Key Details

• Meeting date: April 10, 2026 (Form 8‑K filed April 16, 2026).
• Reverse Stock Split Proposal vote: For 2,096,356; Against 582,185; Abstain 12,852; Broker Non‑Votes 0. Board may choose split ratio between 1‑for‑5 and 1‑for‑500 and effect it within one year.
• Series A Preferred Issuance (Nasdaq Rule 5635(d)) vote: For 1,466,141; Against 203,756; Abstain 8,652; Broker Non‑Votes 1,012,844. Includes approval to issue conversion shares in excess of 19.99% and set conversion floor at 20% of the Minimum Price.
• ELOC Issuance vote: For 1,469,985; Against 203,926; Abstain 4,638; Broker Non‑Votes 1,012,844 — approves issuance of 19.99% or more under the November 11, 2025 Purchase Agreement.
• Authorized Common Stock Increase vote: For 1,925,368; Against 524,501; Abstain 7,403; Broker Non‑Votes 234,122 — increases authorized common from 490M to 700M shares.
• Adjournment authorization vote: For 1,893,737; Against 551,855; Abstain 11,679; Broker Non‑Votes 234,122.

Why It Matters

• The approved reverse split gives the board a tool to consolidate outstanding shares, which can affect per‑share metrics and share price level but does not change a holder’s percentage ownership until implemented.
• Approvals tied to the Series A Preferred and the ELOC Agreement clear the way for issuing significant additional common shares upon conversion or under the financing, which could increase the share count and potentially dilute existing holders.
• Increasing authorized shares to 700 million provides the company flexibility for future financings, equity grants, or other corporate actions, but also enables potential dilution if and when shares are issued.
• Investors should note these are governance approvals; actual dilution, conversion, or a reverse split will occur only if and when the board or convertible holders take the next steps.